IP Library › Granted Patent US 12678507
Granted Patent B2
US 12678507 · App. 17/256,516 · Granted Jul 14, 2026

Protein tyrosine kinase 6 (PTK6) degradation / disruption compounds and methods of use

Inventors: Jian Jin (New York, NY); Hanna Irie (New York, NY); Jing Liu (New York, NY); Yan Xiong (New York, NY); Jessica Byerly (New York, NY); Shannon Tomita (New York, NY); Jianping Hu (New York, NY)
Assignee: Icahn School of Medicine at Mount Sinai
A61K47/545A61K45/06A61P35/00C07D401/14C07D403/02C07D417/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12678507
App. No.
17/256,516
Granted
Jul 14, 2026
Kind
B2
Abstract

Disclosed herein are protein tyrosine kinase 6 (PTK6) degradation/disruption compounds including a PTK6 ligand, a degradation/disruption tag, and a linker, and methods of using such compounds in the treatment of FTK6-mediated diseases.

Claims (2)

1 . Bivalent compound YX39-105 having the following structure:

and pharmaceutically acceptable salts and enantiomers thereof.